Takeda’s first-in-class narcolepsy drug succeeds in two registrational studies

Takeda’s oral orexin agonist has cleared a pair of Phase 3 trials in a sleep disorder, marking the first late-stage win for a drug class that Wall Street analysts say has multi-billion dollar potential. ...